Senlang Bio Announces Completion of RMB 200 Million Financing with Advantech Capital as Exclusive Financial Advisor

Recently, senlangbio announced the completion of a 200 million RMB financing round, exclusively invested by Qianhai Mother Fund. In this transaction, Easy Capital served as the exclusive financial advisor to senlangbio.

Senlangbio is a high-tech biopharmaceutical company that focuses on the research, development, and application of new immune cell therapy technologies, and is committed to the precise treatment of malignant tumors. The funds from this round of financing will mainly be used for the advancement of the company’s existing pipeline, the R&D of new products, and the upgrading and iteration of its technology platform. After the completion of the transaction, Senlangbio will continue to build a complete cell therapy ecosystem that includes upstream technology R&D, midstream cell product production, and downstream clinical transformation.

Senlangbio has a high-level R&D team, a rich library of mature products, a large-scale cell production system, and an expanding network of clinical trial collaborations. Its co-founder and chief scientist, Dr. Jianqiang Li, has many years of overseas R&D work experience.

Currently, Senlangbio has built an efficient cell therapy innovation technology platform, and on this platform, it has developed and produced several leading products including novel CD19-targeted CAR-T, CD7-targeted CAR-T, Combo CAR-T, universal CAR-γδT, as well as therapies targeting solid tumors, for the treatment of major hematological malignancies such as acute lymphoblastic leukemia and lymphoma, and solid tumors like liver cancer.

Among them, the new structure CD19 CAR-T has undergone multiple iterations and upgrades, showing significantly superior performance in treatment safety compared to similar products at home and abroad. This product has entered Phase I clinical trials. The CD7 CAR-T product for relapsed or refractory T-cell leukemia/lymphoma adopts a unique production process, demonstrating excellent safety and efficacy (CR rate > 90%) in IIT studies. Relevant data have been published in the authoritative industry journal *Blood* (Impact Factor: 23.629) and presented as four oral reports and posters at the 2021 American Society of Hematology (ASH) Annual Meeting. Technologically advanced universal CAR-γδT products have also entered the clinical exploration stage. A late-stage AML patient achieved complete remission after receiving senlangbio's universal product treatment.The achievement was selected for poster presentation at this year's European Society for Blood and Marrow Transplantation (EBMT) annual meeting.

Senlangbio has built a 5,000-square-meter CAR-T research center and owns a self-developed nanobody CAR-T development platform. It has an independent product R&D system that covers the entire process, including virus, plasmid, cell culture, testing, and clinical trials. The company is currently working on the design of new workshops, which will subsequently enable large-scale production of its products. Additionally, the company possesses strong clinical transformation capabilities and has established close cooperative relationships with major clinical centers in China, accumulating a good reputation within the industry.

Dr. Jianqiang Li, Chief Scientist and Founder of SenlangbioSenlangbio stated: "Since its establishment in 2016, Senlangbio has continuously broken through innovations, and has been developing cell therapy products with high safety, high efficacy, and low cost for patients. In the future, Senlangbio will continue to prioritize patient needs as the primary R&D goal, accelerate product launches through clinical collaborations with well-known hospitals in China, and build a widely recognized cell therapy brand among the cancer patient community."

Dr. Duan Xufang, Executive Director of Qianhai Mother Fund"Cell therapy will be the most promising field in the next generation of cancer treatment and the hope for achieving a cure for cancer. Senlangbio has a high-level R&D team and commercial operation team, with an integrated technology platform from antibody screening to cell production, a high-quality and extensive clinical cooperation network, and advanced commercial development capabilities. Qianhai Mother Fund is honored to be a witness and participant in the development of Senlangbio, and will support Senlangbio in further advancing clinical trials and product development, committing to providing better treatment options and more comprehensive clinical choices for cancer patients."

Senlangbio, established in January 2016, is located in Shijiazhuang High-tech Zone and has a 5,000-square-meter CAR-T (Chimeric Antigen Receptor T-cell) research center. The company possesses complete processes and technologies in CAR genetic engineering vector preparation, virus packaging, CAR-T production, and clinical applications. Its research level and product quality in the CAR-T field have gained high recognition from international peers, with multiple presentations at the American Society of Hematology Annual Meetings.

Qianhai Mother Fund is a large-scale commercialized mother fund established in accordance with the spirit of "supporting the establishment of Qianhai Equity Investment Mother Fund" as stated in the “Reply of the State Council on Supporting the Development and Opening-up Policies of the Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone in Shenzhen,” and in response to the major trend that China's equity investment mother fund industry is about to embrace a spring of development. The Qianhai Mother Fund gathers influential and resourceful investors (LPs) within China, including governments, insurance and financial investment institutions, well-known enterprises, and listed companies. It also brings together one of the most insightful, experienced, and widely connected management teams in China’s private equity investment sector, with top-tier service capabilities. The partners of the management company all come from leading investment institutions in the industry, possessing an average of over 20 years of investment management experience, managing funds exceeding tens of billions, and boasting top-tier investment performance within the industry.

CEC Capital is a leading investment bank in China's new economy, focusing on the three major industries of TMT, consumer, and healthcare globally. In addition to its investment banking services, CEC Capital manages both a Renminbi fund and a US Dollar fund. The company has offices in Beijing, Shanghai, Los Angeles, and San Francisco, and holds a US securities market license. The healthcare industry is a key focus for CEC Capital and an area where it has significant strengths, having been the new economy investment bank with the most healthcare industry transaction records in China for five consecutive years. Moreover, CEC Capital boasts the largest, most professional, and comprehensively covered healthcare investment banking team in China.